Our technologies

Advanced polymer platforms for medical devices

tech hero
tech hero

Arterius has developed two advanced polymer platforms for use in devices to manage arterial disease while leaving no long-term implants in the body

Polymer coating technology
Balloon with drugs vertical

Arterius’ polymer coating provides the foundation for a significant improvement on DCBs

Ballon blank tips

Delivery of most of the drug contained on the surface of the balloon to the tissue – some currently available DCBs deliver only a small fraction of the drug to the tissue, with most lost systemically during transit to the lesion or remaining on the surface of the balloon when it is withdrawn.

Balloon with drugs vertical

Delivery of more than one drug to the vessel wall – dual drug therapy provides the opportunity for long-term inhibition of restenosis and reduced risk of local thrombus formation.

Balloon with drugs vertical
Approved by regulators

Arterius’ DCB under development is using a balloon catheter that is already approved by regulators, and the coating technology may be applied to any PTA or PTCA balloon platform

Easily transferrable

Arterius’ polymer coating technology is compatible with both types of PTA balloon substrate on the market today (nylon and Pebax™). The platform will be easily transferrable to another balloon substrate, as required

Bioresorbable scaffold

Arterius’ bioresorbable scaffold addresses the problems associated with metal stents and first-generation bioresorbable scaffolds


No long-term stent in the vessel to complicate future revascularisation procedures that may be required

No long-term occlusion of side branches of the stented vessel

ArterioSorb™ is made with PLLA, a universally-approved biocompatible polymer that is widely used for dissolving sutures and soft-tissue implants

Arterius’ patented ‘solid phase orientation’ production process enables ArterioSorb™ to address the issues associated with the early generation of bioresorbable scaffolds
BRS severe dis

It provides comparable radial force to a metal stent for 3–6 months while the vessel remodels


Strut thickness of only 95 microns reduces risk of thrombosis – which can be further reduced by the application of anti-platelet drug using Arterius’ polymer coating

Crimped BRS at lesion

It is highly flexible, facilitating navigation to the target lesion through tortuous anatomy

BRS cells

The scaffold design uses larger cells towards the extremities providing maximal flexibility and smaller cells in the centre to provide maximal structural support to the target lesion

The scaffold can be manufactured in a wide range of lengths with diameter from 2–8mm making it suitable for a broad range of lesions

[object Object]
BRS severe dis
Future development
Arterius is developing the ArterioSorb™ platform for peripheral arterial disease in the lower limbs.


Arterius is planning First in Human studies with its Drug Coated Balloon and Bioresorbable Scaffold products. If you are interested in partnering for these studies, please contact us.

tech dev